The year 2024 has begun on a muted note in terms of FDA approvals, with only one novel drug getting endorsed in January. Let's take a look at the biotech companies that are awaiting FDA word on their drug candidates in February.
Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors.
Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study.